KISS
Kisspeptin-10
The C-terminal decapeptide of kisspeptin, the product of the KISS1 gene, amidated at the C-terminus. This fragment carries the full activity of the longer parent peptide at KISS1R, the G-protein-coupled receptor formerly called GPR54.
Kisspeptin-10 has 5 registered human studies on ClinicalTrials.gov, reaching phase 3, covering 59 planned or enrolled participants across the 5 studies that published a figure. No FDA-approved product contains Kisspeptin-10. 154 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Kisspeptin-10; the registry search is fuzzy, so every match is re-checked. None of this says whether Kisspeptin-10 works or is safe.
FDA status
Research only
Human studies
5
Furthest phase
Phase 3
Papers, 10 yr
154
Readership
—
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
5
Registered human studies
Phase 3
Furthest phase reached
59
Planned or enrolled participants, across 5 studies that published a figure
None
No FDA-approved product contains it
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Kisspeptin-10 is, and what it has been studied for
Kisspeptin-10 is classified by ChEMBL as a protein, and appears in trial registrations under HUMAN METASTIN 45-54. Its FDA substance identifier is FS1N52VS3S.
Across 5 registered trials, it has been studied in Insulin, Glucose, Healthy Volunteers and Women. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Quaid-e-Azam University and Stephanie B. Seminara, MD among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Kisspeptin-10 reached Phase 3 across 5 registered trials.
No FDA-approved product contains Kisspeptin-10. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Kisspeptin-10?
Papers published each year that name Kisspeptin-10 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 26 | 0 | Yes |
| 2018 | 22 | 0 | Yes |
| 2019 | 16 | 1 | Yes |
| 2020 | 19 | 0 | Yes |
| 2021 | 13 | 0 | Yes |
| 2022 | 20 | 1 | Yes |
| 2023 | 11 | 0 | Yes |
| 2024 | 10 | 0 | Yes |
| 2025 | 21 | 0 | Yes |
| 2026 | 15 | 0 | No |
154 papers and 2 registered trials between 2017 and 2026. A paper counts when “Kisspeptin-10” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Kisspeptin-10
154 indexed papers name Kisspeptin-10 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry
- Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src
- Author Correction: Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src
- Kisspeptin-10 increases collagen content in the myocardium by focal adhesion kinase activity
- Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice
- Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion
- Kisspeptin-10 in cryodiluent improves the post-thaw quality of Nili-Ravi buffalo (Bubalus bubalis) bull spermatozoa
- Kisspeptin-10 protects against HIV-1 Tat-induced blood-brain barrier dysfunction and neuroinflammation via RhoA/ROCK pathway: Implications for HAND therapy
Collected 2026-08-02from PubMed, phrase-matched on “Kisspeptin-10” in title and abstract. Run the same search.
About Kisspeptin-10
The C-terminal decapeptide of kisspeptin, the product of the KISS1 gene, amidated at the C-terminus. This fragment carries the full activity of the longer parent peptide at KISS1R, the G-protein-coupled receptor formerly called GPR54.
- Also known as
- Metastin 45-54 · KP-10
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.